



## **Pre - PA Allowance**

None

---

## **Prior-Approval Requirements**

**Age** 18 years of age and older

### **Diagnosis**

Patient must have the following:

Metastatic non-small cell lung cancer (NSCLC)

**AND ALL** of the following:

1. Tumor must have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations as detected by an FDA-approved test
2. Prescriber agrees to monitor for serious adverse reactions including interstitial lung disease (ILD)/pneumonitis, diarrhea, and dermatologic reactions

## **Prior - Approval Limits**

**Quantity** 90 tablets per 90 days

**Duration** 12 months

---

## **Prior – Approval *Renewal* Requirements**

**Age** 18 years of age and older

### **Diagnosis**

Patient must have the following:

**Metastatic non-small cell lung cancer (NSCLC)**

**AND ALL** of the following:

1. **NO** disease progression or unacceptable toxicity
2. Prescriber agrees to monitor for serious adverse reactions including interstitial lung disease (ILD)/pneumonitis, diarrhea, and dermatologic reactions



**BlueCross.  
BlueShield.**

Federal Employee Program.

**VIZIMPRO  
(dacomitinib)**

## **Prior - Approval *Renewal* Limits**

Same as above